Trial reportJournal of hypertension2026
Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension.
Trial report in Journal of hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmbulatory blood pressure measurement (ABPM) data from the PRECISION study have shown that in patients with confirmed resistant hypertension (RHT), aprocitentan leads to substantial lowering of BP, particularly at night-time. Here, the ABPM data were used to define subgroups with substantial prognostic value (dipping pattern, BP load, heart rate, arterial stiffness, and salt sensitivity) and to evaluate the BP-lowering effect of aprocitentan on these subgroups.
methodsThe effects of aprocitentan on ABPM derivatives including dipping pattern, BP load, and heart rate were evaluated. The BP lowering effect of aprocitentan was assessed based on the subject's baseline arterial stiffness and salt sensitivity.
resultsAt week 4, the placebo-corrected and dose-dependent decrease of ambulatory systolic BP was more marked for baseline non-dippers than dippers. The proportion of non-dippers at baseline whose dipping pattern normalized at week 4 was higher for the aprocitentan group compared to placebo. The decrease in BP load during daytime/nighttime was also more pronounced with aprocitentan compared to placebo. Despite the BP lowering effect of aprocitentan, heart rate remained unchanged at week 36. The BP lowering effect of aprocitentan was not diminished by increased arterial stiffness index or salt sensitivity risk at baseline.
conclusionIn addition to a significant and sustained day and night-time ambulatory BP reduction, aprocitentan was associated with a higher proportion of patients experiencing dipping pattern normalization and more pronounced BP load reduction, indicating prognostic relevance. Increased arterial stiffness or salt sensitivity did not alter the BP response to aprocitentan, suggesting additional clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.